Speakers | Kisaco Research

Speakers

Animal Health, Nutrition and Technology Innovation Europe 2024
4-6 March, 2024
London, UK
  • Author:

    Kristin Peck

    Chief Executive Officer
    Zoetis

    Kristin Peck

    Chief Executive Officer
    Zoetis
  • Author:

    Jeff Simmons

    Chief Executive Officer
    Elanco

    Jeff Simmons

    Chief Executive Officer
    Elanco
  • Author:

    Robert Kelly

    Senior Vice President, Commercial Leader for EURAM Region
    MSD

    Robert Kelly

    Senior Vice President, Commercial Leader for EURAM Region
    MSD
  • Author:

    Laetitia Cicchelero

    Cross-Health Coordinator
    Ghent University

    Laetitia Cicchelero

    Cross-Health Coordinator
    Ghent University
  • Author:

    Matt Dobbs

    Global Chief Medical Officer
    Destination Pet

    Matt Dobbs

    Global Chief Medical Officer
    Destination Pet
  • Author:

    Simon Doherty

    Associate Fellow
    Queen’s University Belfast

    Simon Doherty

    Associate Fellow
    Queen’s University Belfast
  • Author:

    Vinicius Chiappetta

    Global Commercial Director – Cargill Digital Solutions
    Cargill

    Vinicius Chiappetta

    Global Commercial Director – Cargill Digital Solutions
    Cargill
  • Author:

    Dave Ross

    Chief Executive Officer
    Agri-EPI Centre Ltd

    Dave Ross

    Chief Executive Officer
    Agri-EPI Centre Ltd
  • Author:

    Jamie Brannan

    EVP and President International Operations and Aquaculture
    Zoetis

    Jamie Brannan

    EVP and President International Operations and Aquaculture
    Zoetis
  • Author:

    Mariama Boumanjal

    Start-up Partner Manager
    Google

    Mariama Boumanjal

    Start-up Partner Manager
    Google
  • Author:

    Julia Stephanus

    Partner
    Borealis Ventures

    Julia Stephanus is a 30 year veteran of the veterinary pharmaceutical industry.  Currently Julia is President of Avviare, a consulting firm specializing in supporting veterinary focused start-ups. 

    Julia has been involved in the development and launch of 28 veterinary products.  She has been a senior executive in two start-up pharmaceutical companies (Aratana Therapeutics and Summit VetPharm), and held key positions at multi-nationals including Pfizer (now Zoetis) and its legacy companies.

    As Chief Commercial Officer of Aratana Julia provided the commercial leadership resulting in a successful IPO (NASDAQ:PETX), high-impact corporate branding, innovative go-to-market strategies for five therapeutics and the staffing of the inaugural commercial organization.

    As founder and CEO of Summit VetPharm, Julia developed and launched a new line of companion animal parasiticides, grew the company to a cash flow positive position with 85 employees in five years and divested the company to Ceva Animal Health in 2010.  A graduate of Indiana University, she has continued her executive training at Harvard, Columbia, University of Chicago and the Wharton School of Business.      

    Julia Stephanus

    Partner
    Borealis Ventures

    Julia Stephanus is a 30 year veteran of the veterinary pharmaceutical industry.  Currently Julia is President of Avviare, a consulting firm specializing in supporting veterinary focused start-ups. 

    Julia has been involved in the development and launch of 28 veterinary products.  She has been a senior executive in two start-up pharmaceutical companies (Aratana Therapeutics and Summit VetPharm), and held key positions at multi-nationals including Pfizer (now Zoetis) and its legacy companies.

    As Chief Commercial Officer of Aratana Julia provided the commercial leadership resulting in a successful IPO (NASDAQ:PETX), high-impact corporate branding, innovative go-to-market strategies for five therapeutics and the staffing of the inaugural commercial organization.

    As founder and CEO of Summit VetPharm, Julia developed and launched a new line of companion animal parasiticides, grew the company to a cash flow positive position with 85 employees in five years and divested the company to Ceva Animal Health in 2010.  A graduate of Indiana University, she has continued her executive training at Harvard, Columbia, University of Chicago and the Wharton School of Business.      

  • Author:

    Ellen de Brabander

    Executive Vice President R&D and Innovation
    Elanco

    Ellen de Brabander

    Executive Vice President R&D and Innovation
    Elanco
  • Author:

    Sven Arnouts

    Business Development
    Ghent University

    Sven Arnouts

    Business Development
    Ghent University
  • Author:

    Justine Conway

    Global Head of Business Development
    Elanco

    Justine Conway

    Global Head of Business Development
    Elanco
  • Author:

    Lawrence Brown

    Senior Technical and Account Manager
    Anpario

    Dr Lawrence Brown is a Sector Specialist (Animal Sciences & Aquaculture) for the Department for International Trade. His main focus is on inward investment into the UK but also assists with trade. Lawrence is a qualified veterinary surgeon and consultant, working with private and public sector clients through his consultancy company LJB Veterinary Services Ltd. He is an elected member of the British Veterinary Association's (BVA) Scottish Council and is studying for an Executive MBA at the University of Edinburgh.

    Lawrence Brown

    Senior Technical and Account Manager
    Anpario

    Dr Lawrence Brown is a Sector Specialist (Animal Sciences & Aquaculture) for the Department for International Trade. His main focus is on inward investment into the UK but also assists with trade. Lawrence is a qualified veterinary surgeon and consultant, working with private and public sector clients through his consultancy company LJB Veterinary Services Ltd. He is an elected member of the British Veterinary Association's (BVA) Scottish Council and is studying for an Executive MBA at the University of Edinburgh.

  • Author:

    Ivan Farneti

    Founding Partner
    Five Season Ventures

    Ivan has been an active venture capital investor for the last 20 years and he is the co-founder of Five Seasons Ventures, the first European venture fund fully focused on Foodtech.

    He is passionate about product and technology innovation aimed at solving big challenges in the food industry: from alternative sources of proteins, to functional foods, from new models of food distribution to the reduction of food waste.  At Five Seasons he invested in Tropic Biosciences (plants gene editing), Butternut Box (DNVB pet nutrition), THIS.co (plant-based meat alternatives), Cortilia (D2C fresh food retailer), YFood Labs (balanced meal replacements), Just Spices (D2C spices), Yamo (D2C fresh baby food) and La Fourche (D2C organic groceries).

    His experience from previous venture funds in London, includes structuring investments, organizational and strategy development, setting up governance for growth and planning for successful exits. He was an early stage investor in Everbridge, Inc. (Nasdaq: EVBG), Tridion (acq. by SDL Plc), Gomez (acq. by Compuware), among others.

    In his spare time he enjoys family life, cooking, fly fishing, and practicing jiu-jitsu with his son Adam.

     

     

    Ivan Farneti

    Founding Partner
    Five Season Ventures

    Ivan has been an active venture capital investor for the last 20 years and he is the co-founder of Five Seasons Ventures, the first European venture fund fully focused on Foodtech.

    He is passionate about product and technology innovation aimed at solving big challenges in the food industry: from alternative sources of proteins, to functional foods, from new models of food distribution to the reduction of food waste.  At Five Seasons he invested in Tropic Biosciences (plants gene editing), Butternut Box (DNVB pet nutrition), THIS.co (plant-based meat alternatives), Cortilia (D2C fresh food retailer), YFood Labs (balanced meal replacements), Just Spices (D2C spices), Yamo (D2C fresh baby food) and La Fourche (D2C organic groceries).

    His experience from previous venture funds in London, includes structuring investments, organizational and strategy development, setting up governance for growth and planning for successful exits. He was an early stage investor in Everbridge, Inc. (Nasdaq: EVBG), Tridion (acq. by SDL Plc), Gomez (acq. by Compuware), among others.

    In his spare time he enjoys family life, cooking, fly fishing, and practicing jiu-jitsu with his son Adam.

     

     

  • Author:

    Karolina Zapadka

    Investor
    Park Walk Advisors

    Karolina Zapadka

    Investor
    Park Walk Advisors
  • Author:

    Gentiane Gorlier

    General Partner
    The Yield Lab

    Gentiane Gorlier

    General Partner
    The Yield Lab
  • Author:

    Richard Casey

    Executive Director
    World Small Animal Veterinary Association

    Richard Casey

    Executive Director
    World Small Animal Veterinary Association
  • Author:

    Samuel Laing

    Technology Development
    Avara Foods

    Samuel Laing

    Technology Development
    Avara Foods
  • Author:

    Jamie Stein

    Co-Founder
    Devonian Capital

    Jamie Stein

    Co-Founder
    Devonian Capital
  • Author:

    Marcio Kanas

    Executive Director
    Nomura Bank

    Marcio Kanas

    Executive Director
    Nomura Bank
  • Author:

    Linda Rhodes

    VMD, PhD, Independent and ex-CSO
    Independent Animal Health

    Dr. Rhodes has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.

    Dr. Rhodes was educated at the University of Pennsylvania School of Veterinary Medicine (VMD) and Cornell University (PhD). She has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine. She has an extensive background in physiology, veterinary medicine, and molecular biology. As a senior research fellow at Merck Research Laboratories for 10 years, she led pre-clinical biology evaluation of several marketed human drugs. Dr. Rhodes practiced clinical veterinary medicine for five years, with experience in both companion and farm animal practice. She worked for Merial Ltd. as director of development projects, leading project teams developing novel compounds for a variety of indications and headed new technology assessment, leading the evaluation of licensing opportunities. In April 2001, she formed AlcheraBio, a consulting, marketing, communications and contract research firm specializing in developing new drugs for animals, working with biotechnology and animal health companies, with clients in the US, European Union, Canada and Australia. AlcheraBio was acquired in 2008 by Argenta, and in 2011, Dr. Rhodes accepted a position as CEO of Aratana Therapeutics, a company developing innovative new medicines for dogs and cats, and subsequently, when the company became public (PETX) served as its Chief Scientific Officer. During her tenure, development was completed on three new pet therapeutics: two new molecules with novel mechanisms of actions were approved by the FDA, and a third drug had FDA registration completed and was approved in August, 2016. She is currently retired and an independent consultant. She is a member of the Board of Directors of ImmuCell (NASDAQ: ICCC) and the Alliance for Contraception in Dogs and Cats, serves on the Scientific Advisory Board of the Found Animals Foundation. She is an adjunct faculty member in the Graduate Animal Science program at Rutgers University.

    Linda Rhodes

    VMD, PhD, Independent and ex-CSO
    Independent Animal Health

    Dr. Rhodes has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.

    Dr. Rhodes was educated at the University of Pennsylvania School of Veterinary Medicine (VMD) and Cornell University (PhD). She has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine. She has an extensive background in physiology, veterinary medicine, and molecular biology. As a senior research fellow at Merck Research Laboratories for 10 years, she led pre-clinical biology evaluation of several marketed human drugs. Dr. Rhodes practiced clinical veterinary medicine for five years, with experience in both companion and farm animal practice. She worked for Merial Ltd. as director of development projects, leading project teams developing novel compounds for a variety of indications and headed new technology assessment, leading the evaluation of licensing opportunities. In April 2001, she formed AlcheraBio, a consulting, marketing, communications and contract research firm specializing in developing new drugs for animals, working with biotechnology and animal health companies, with clients in the US, European Union, Canada and Australia. AlcheraBio was acquired in 2008 by Argenta, and in 2011, Dr. Rhodes accepted a position as CEO of Aratana Therapeutics, a company developing innovative new medicines for dogs and cats, and subsequently, when the company became public (PETX) served as its Chief Scientific Officer. During her tenure, development was completed on three new pet therapeutics: two new molecules with novel mechanisms of actions were approved by the FDA, and a third drug had FDA registration completed and was approved in August, 2016. She is currently retired and an independent consultant. She is a member of the Board of Directors of ImmuCell (NASDAQ: ICCC) and the Alliance for Contraception in Dogs and Cats, serves on the Scientific Advisory Board of the Found Animals Foundation. She is an adjunct faculty member in the Graduate Animal Science program at Rutgers University.

  • Author:

    Jo Malone

    Chief Executive Officer
    Vet Partners

    Jo qualified from Glasgow vet school in 1998, she has been actively involved in both clinical and all business aspects of veterinary life throughout her career. Jo has worked for Minster Vets for the last 16 years focusing on small animal clinical practice.

     

    In the last 10 years she has become increasingly involved in managing the practice alongside her clinical role. Being instrumental in growing the practice, improving performance and developing the people within the practice. Jo is passionate about the veterinary profession and the people involved in it.

     

    In 2015 she became Managing Director of VetPartners and then CEO in 2016.

    Jo Malone

    Chief Executive Officer
    Vet Partners

    Jo qualified from Glasgow vet school in 1998, she has been actively involved in both clinical and all business aspects of veterinary life throughout her career. Jo has worked for Minster Vets for the last 16 years focusing on small animal clinical practice.

     

    In the last 10 years she has become increasingly involved in managing the practice alongside her clinical role. Being instrumental in growing the practice, improving performance and developing the people within the practice. Jo is passionate about the veterinary profession and the people involved in it.

     

    In 2015 she became Managing Director of VetPartners and then CEO in 2016.

  • Author:

    Katrina Hayter

    Challenge Director
    Innovate UK

    Katrina Hayter

    Challenge Director
    Innovate UK
  • Author:

    Edward Chandler

    Founding Partner
    Fremman Capital

    Edward Chandler

    Founding Partner
    Fremman Capital
  • Author:

    Andre Jordao

    Founder and CEO
    Barkyn

    Andre is an experienced entrepreneur and the CEO of Barkyn, a pet food subscription combining personalised food and telemedicine, growing in multiple European countries.

    Andre Jordao

    Founder and CEO
    Barkyn

    Andre is an experienced entrepreneur and the CEO of Barkyn, a pet food subscription combining personalised food and telemedicine, growing in multiple European countries.

  • Author:

    Cees Jan Hollander

    Global Farming Expertise Manager
    Danone

    Cees Jan Hollander

    Global Farming Expertise Manager
    Danone
  • Author:

    Julie Fitzpatrick

    Scientific Director
    Moredun Research Institute

    Julie Fitzpatrick

    Scientific Director
    Moredun Research Institute
  • Author:

    Bradley Ringeisen

    Executive Director
    Innovative Genomics Institute

    Bradley Ringeisen

    Executive Director
    Innovative Genomics Institute
  • Author:

    Jon Lowe

    Chief Executive Officer
    Axiota Animal Health

    Jon Lowe

    Chief Executive Officer
    Axiota Animal Health
  • Author:

    Jason Johnson

    President & Global Chief Medical Officer
    IDEXX

    Jason Johnson

    President & Global Chief Medical Officer
    IDEXX
  • Author:

    Julie Lawless

    President
    Lawless Strategic Communications

    Julie Lawless

    President
    Lawless Strategic Communications
  • Author:

    Kate Price

    Executive Coach and Organizational Development Consultant
    Dr Kate Price Consulting

    Kate Price

    Executive Coach and Organizational Development Consultant
    Dr Kate Price Consulting
  • Author:

    Apryle Horbal

    President
    VetNOW Virtual Care

    Apryle Horbal

    President
    VetNOW Virtual Care
  • Author:

    Isabelle Delannoy

    Project Leader
    Phibro Animal Health

    Isabelle Delannoy

    Project Leader
    Phibro Animal Health
  • Author:

    Christie Chavis

    Vice President, Animal Nutrition and Health Performance Solutions
    DSM

    Christie Chavis

    Vice President, Animal Nutrition and Health Performance Solutions
    DSM
  • Author:

    Hayden Montgomery

    Agriculture Programme Director
    Global Methane Hub

    Hayden Montgomery

    Agriculture Programme Director
    Global Methane Hub
  • Author:

    Laëtitia Gerbe

    Partner
    Seventure Partners

    Laëtitia Gerbe

    Partner
    Seventure Partners
  • Author:

    Robert DiMarzo

    Principle
    DiMarzo Consulting

    Robert DiMarzo

    Principle
    DiMarzo Consulting
  • Author:

    Greg Blair

    Vice President of Business Development
    Zomedica

    Greg Blair

    Vice President of Business Development
    Zomedica
  • Author:

    Charlie Barton

    Co-Founder
    Virtual Recall

    Charlie Barton

    Co-Founder
    Virtual Recall
  • Author:

    Brian Lindsay

    Director
    Dairy Sustainability Framework

    Brian Lindsay

    Director
    Dairy Sustainability Framework
  • Author:

    Sébastien Huron

    Chairman of the Executive Board and CEO
    Virbac Santé Animale

    Sébastien Huron

    Chairman of the Executive Board and CEO
    Virbac Santé Animale
  • Author:

    Deborah Dullen

    President and CEO
    BioTraceIT

    Deborah Dullen

    President and CEO
    BioTraceIT
  • Author:

    Catriona Curtis

    Group Sustainability and Social Value Manager
    Pets at Home

    Catriona Curtis

    Group Sustainability and Social Value Manager
    Pets at Home
  • Author:

    Sven Smit

    Chair
    McKinsey Global Institute

    Sven Smit

    Chair
    McKinsey Global Institute
  • Author:

    Nicky Deasy

    Investment Committee Member
    Biotope by VIB

    Nicky Deasy

    Investment Committee Member
    Biotope by VIB
  • Author:

    Greg Michel

    Investment Partner
    Cell Capital

    Greg Michel

    Investment Partner
    Cell Capital
  • Author:

    Bruce Truman

    President and Founder
    BLT Technology & Innovation Group

    Bruce Truman

    President and Founder
    BLT Technology & Innovation Group
  • Author:

    John Kirkpatrick

    Agricultural Manager
    Tesco

    John Kirkpatrick

    Agricultural Manager
    Tesco
  • Author:

    David Hallas

    Chief Executive Officer
    ECO Animal Health

    David Hallas

    Chief Executive Officer
    ECO Animal Health
  • Author:

    Edgar Goluch

    Founder and CEO
    QSM Diagnostics

    Edgar Goluch

    Founder and CEO
    QSM Diagnostics
  • Author:

    Dr. Lenore Bacek

    Senior Director of Clinical Affairs
    BluePearl Veterinary Hospital

    Dr. Lenore Bacek

    Senior Director of Clinical Affairs
    BluePearl Veterinary Hospital
  • Author:

    Marie-Paul Lachaud

    Referent Animal Health R&D
    One Health Pharma

    Marie-Paul Lachaud, DVM is Head of Program Management Europe at Aratana Therapeutics. Her responsibilities include coordinating the process leading to regulatory approval by the European Medicines Agency for Aratana’s products targeted at unmet medical needs in cats and dogs.

    Prior to joining Aratana, Dr. Lachaud served the veterinary pharmaceutical industry as an experienced consultant, with a specific focus on international drug clinical development. 

    From 2000 to 2008, Dr. Lachaud was the European animal health director at ICON Clinical Research in Paris, France. In 1990, she co-founded PROTOCOLE, the first European veterinary consultancy and contract research organization focused on drug clinical development and regulatory affairs, which was acquired by ICON in 2000. 

    Dr. Lachaud has been involved in transitioning human drugs to meet unmet needs in veterinary medicine for years. Her work has resulted in significant animal health product approvals in Europe and the United-States for companion animals in a number of innovative therapeutic areas, including reproduction, chronic heart failure, chronic kidney disease, pain management, oncology and neurobehavioral disorders. 

    She received her veterinary degree from Alfort National Veterinary School in Paris and her doctorate in veterinary medicine from the University of Paris, France.

     

    Marie-Paul Lachaud

    Referent Animal Health R&D
    One Health Pharma

    Marie-Paul Lachaud, DVM is Head of Program Management Europe at Aratana Therapeutics. Her responsibilities include coordinating the process leading to regulatory approval by the European Medicines Agency for Aratana’s products targeted at unmet medical needs in cats and dogs.

    Prior to joining Aratana, Dr. Lachaud served the veterinary pharmaceutical industry as an experienced consultant, with a specific focus on international drug clinical development. 

    From 2000 to 2008, Dr. Lachaud was the European animal health director at ICON Clinical Research in Paris, France. In 1990, she co-founded PROTOCOLE, the first European veterinary consultancy and contract research organization focused on drug clinical development and regulatory affairs, which was acquired by ICON in 2000. 

    Dr. Lachaud has been involved in transitioning human drugs to meet unmet needs in veterinary medicine for years. Her work has resulted in significant animal health product approvals in Europe and the United-States for companion animals in a number of innovative therapeutic areas, including reproduction, chronic heart failure, chronic kidney disease, pain management, oncology and neurobehavioral disorders. 

    She received her veterinary degree from Alfort National Veterinary School in Paris and her doctorate in veterinary medicine from the University of Paris, France.

     

  • Author:

    Marijn Hendrickx

    Managing Director
    TerraProtein Equity Proteins

    Marijn Hendrickx

    Managing Director
    TerraProtein Equity Proteins
  • Author:

    Matthieu Frechin

    Chief Executive Officer
    Vetoquinol

    Matthieu Frechin

    Chief Executive Officer
    Vetoquinol
  • Author:

    Rob Readnour

    Managing Director
    Mountain Group Capital Partners

    Dr. Readnour currently serves on or has visitation rights to the following companies: AgTech Accelerator, a unique startup accelerator focused on discovering and developing emerging agricultural technology companies, Skyline Vet Pharma, a company that is developing veterinary pharmaceuticals using proven delivery technologies to reformulate drugs with established animal health markets, and Boragen, a company that is developing small molecule approaches focused on leveraging the unique chemical properties of boron chemistry, both in crop protection and animal health.

    Prior to joining MGP, Dr. Readnour worked at Elanco Animal Health for 27 years. During his Elanco tenure, he held several senior management positions in which he was responsible for developing and executing Elanco’s Research and Development strategies for entering several new business areas (companion animal pharmaceuticals, vaccines and enzymes). In 2017, these new business areas accounted for nearly 50% of Elanco’s $3.0 billion in sales. Dr. Readnour played an important role in Elanco’s acquisition and integration of Novartis Animal Health, Lohmann Animal Health, ChemGen and Janssen Animal Health. Within Elanco, Dr. Readnour led several initiatives to transform Research and Development through the piloting of new approaches to developing animal health products. He developed and led Elanco’s new technology scouting, acquisition and due diligence efforts. He pioneered a lean product development model which allowed Elanco to enter new areas of business without significant capital investment. He led initial efforts for Elanco to invest in early stage companies and partner with external funding sources to develop products with minimal initial investment from Elanco. Dr. Readnour served as a member of the Food and Agriculture Section of Bio International Board and as an External Advisory Board member for University of Illinois Animal Science Department.
    Prior to entering management in Elanco, Dr. Readnour was an internationally recognized expert on animal health product development, analytical chemistry, human food safety and drug residues with 11 publications and 14 external presentations. Throughout his career, Dr. Readnour was responsible for the development and commercialization of 10 animal health products. Dr. Readnour received his PhD in Analytical Chemistry from University of Illinois in 1990.

    Rob Readnour

    Managing Director
    Mountain Group Capital Partners

    Dr. Readnour currently serves on or has visitation rights to the following companies: AgTech Accelerator, a unique startup accelerator focused on discovering and developing emerging agricultural technology companies, Skyline Vet Pharma, a company that is developing veterinary pharmaceuticals using proven delivery technologies to reformulate drugs with established animal health markets, and Boragen, a company that is developing small molecule approaches focused on leveraging the unique chemical properties of boron chemistry, both in crop protection and animal health.

    Prior to joining MGP, Dr. Readnour worked at Elanco Animal Health for 27 years. During his Elanco tenure, he held several senior management positions in which he was responsible for developing and executing Elanco’s Research and Development strategies for entering several new business areas (companion animal pharmaceuticals, vaccines and enzymes). In 2017, these new business areas accounted for nearly 50% of Elanco’s $3.0 billion in sales. Dr. Readnour played an important role in Elanco’s acquisition and integration of Novartis Animal Health, Lohmann Animal Health, ChemGen and Janssen Animal Health. Within Elanco, Dr. Readnour led several initiatives to transform Research and Development through the piloting of new approaches to developing animal health products. He developed and led Elanco’s new technology scouting, acquisition and due diligence efforts. He pioneered a lean product development model which allowed Elanco to enter new areas of business without significant capital investment. He led initial efforts for Elanco to invest in early stage companies and partner with external funding sources to develop products with minimal initial investment from Elanco. Dr. Readnour served as a member of the Food and Agriculture Section of Bio International Board and as an External Advisory Board member for University of Illinois Animal Science Department.
    Prior to entering management in Elanco, Dr. Readnour was an internationally recognized expert on animal health product development, analytical chemistry, human food safety and drug residues with 11 publications and 14 external presentations. Throughout his career, Dr. Readnour was responsible for the development and commercialization of 10 animal health products. Dr. Readnour received his PhD in Analytical Chemistry from University of Illinois in 1990.

  • Author:

    Stephen Lesser

    Principal
    Novaquest Capital Management

    Stephen Lesser

    Principal
    Novaquest Capital Management
  • Author:

    Tina Sejersgård Fanø

    Executive Vice President, Agriculture & Industrial BioSolutions
    Novozymes

    Tina Sejersgård Fanø

    Executive Vice President, Agriculture & Industrial BioSolutions
    Novozymes
  • Author:

    Rimma Driscoll

    Executive Vice President and Head of Global Strategy, Commercial and Business Development
    Zoetis

    Rimma Driscoll is an executive in Global Business Development and Strategic Alliances with 20+ years in the field. Rimma has a depth of experience in a broad range of global transactions including JVs,Strategic Alliances, Collaborations, Acquisitions, Divestitures, Licensing Deals, and Partnerships. This experience span from small Discovery deals to multi-billionaire dollar divestitures. Rimma guides Multi-function teams on the external strategies and then leads all aspects of negotiations, and leverages external relationships to bring transactions to closure. She has worked extensively in Pharmaceuticals, Consumer Healthcare and Consumer Products businesses.

    Rimma Driscoll

    Executive Vice President and Head of Global Strategy, Commercial and Business Development
    Zoetis

    Rimma Driscoll is an executive in Global Business Development and Strategic Alliances with 20+ years in the field. Rimma has a depth of experience in a broad range of global transactions including JVs,Strategic Alliances, Collaborations, Acquisitions, Divestitures, Licensing Deals, and Partnerships. This experience span from small Discovery deals to multi-billionaire dollar divestitures. Rimma guides Multi-function teams on the external strategies and then leads all aspects of negotiations, and leverages external relationships to bring transactions to closure. She has worked extensively in Pharmaceuticals, Consumer Healthcare and Consumer Products businesses.

  • Author:

    Ben North

    Director of Portfolio and Innovation Strategy
    PHARMAQ

    Ben holds the position of Director of Portfolio and Innovation Strategy at PHARMAQ, the aquaculture health business of Zoetis. Ben has worked for PHARMAQ since 2008 and held a variety of technical and commercial roles, including 7 years as the Country Manager of PHARMAQ’s UK business. In 2017 Ben moved across full time to PHARMAQ’s Oslo-based R&D organisation as R&D Portfolio Director, before taking on the current role in 2020, which is focused on delivering an overarching innovation strategy across the continuum of care for aquaculture health.

    Before joining PHARMAQ, Ben worked as a post-doctorate researcher at the Stirling University, where he also undertook his PhD. The focus of Ben’s research was investigating the impact of husbandry factors such as stocking density and water quality on fish welfare. This research identified operational welfare indicators for fish in commercial aquaculture systems and generated welfare indices by combining a range of objective indicators. Ben also holds a BSc in Marine Biology, an MSc in Aquaculture and in 2018 completed an Executive MBA program at Warwick Business School.

    Ben North

    Director of Portfolio and Innovation Strategy
    PHARMAQ

    Ben holds the position of Director of Portfolio and Innovation Strategy at PHARMAQ, the aquaculture health business of Zoetis. Ben has worked for PHARMAQ since 2008 and held a variety of technical and commercial roles, including 7 years as the Country Manager of PHARMAQ’s UK business. In 2017 Ben moved across full time to PHARMAQ’s Oslo-based R&D organisation as R&D Portfolio Director, before taking on the current role in 2020, which is focused on delivering an overarching innovation strategy across the continuum of care for aquaculture health.

    Before joining PHARMAQ, Ben worked as a post-doctorate researcher at the Stirling University, where he also undertook his PhD. The focus of Ben’s research was investigating the impact of husbandry factors such as stocking density and water quality on fish welfare. This research identified operational welfare indicators for fish in commercial aquaculture systems and generated welfare indices by combining a range of objective indicators. Ben also holds a BSc in Marine Biology, an MSc in Aquaculture and in 2018 completed an Executive MBA program at Warwick Business School.

  • Author:

    Juan-Carlos Carrillo Peláez

    Senior Toxicologist
    Shell

    Juan-Carlos Carrillo Peláez

    Senior Toxicologist
    Shell
  • Author:

    Martin Sutcliffe

    Aquaculture Specialist
    CIEL

    Martin Sutcliffe

    Aquaculture Specialist
    CIEL
  • Author:

    Adrienne Woodward

    Manager of Swine – Specialty Product Research
    United Animal Health

    Adrienne Woodward

    Manager of Swine – Specialty Product Research
    United Animal Health
  • Author:

    Dr. Kimberly Simmons

    Director Global Regulatory Affairs
    Clinglobal

    Dr. Kimberly Simmons

    Director Global Regulatory Affairs
    Clinglobal
  • Author:

    Udi Cohen

    Leader
    MSD Animal Health Technology Labs

    Udi Cohen

    Leader
    MSD Animal Health Technology Labs
  • Author:

    Ian Tarpey

    Vice President Biologicals R&D
    MSD Animal Health

    Ian Tarpey

    Vice President Biologicals R&D
    MSD Animal Health
  • Author:

    Laurie Hueneke

    Executive Director, Animal Health Public Policy & Government Relations
    MSD Animal Health

    Laurie Hueneke

    Executive Director, Animal Health Public Policy & Government Relations
    MSD Animal Health
  • Author:

    Alan Beynon

    Leader
    SenseHub Poultry, MSD Animal Health

    Alan Beynon

    Leader
    SenseHub Poultry, MSD Animal Health
  • Author:

    Aaron Schacht

    CEO
    BIomEdit

    Prior to this role, Mr. Aaron Schacht was the Vice President of Global Research and Development / Regulatory Affairs at Elanco Animal Healthheld. Before that, he held the role of Global Brand Development Leader – Pain in Lilly Biomedicines. He was the global leader for product development and commercialization activities for LY2951742 – Lilly’s novel CGRP neutralizing antibody – a new potential treatment for prevention of Migraine and Cluster Headache. In 2012, Schacht joined Lilly Biomedicines as Senior Advisor – Strategy & Business Development for Lilly BioMedicines. His responsibilities included oversight of Therapeutic Strategy development, R&D Portfolio Management, and Business Development for Lilly BioMedicines – Lilly’s largest business unit. Past roles included serving as Executive Director, Global External R&D, at Eli Lilly and Company, where he was responsible for implementation of strategies which aim to leverage novel approaches to external partnerships to augment Lilly’s access to pharmaceutical innovation as well as Executive Director of LRL (Lilly Research Labs) Strategy, Portfolio Management and Project Management where he was responsible for strategic planning, R&D portfolio and project management. Prior to these roles, he was Director, Innovation Center in the eLilly organization where he focused on the exploration, incubation and implementation of new business models and capabilities relevant to the strategic evolution of the pharmaceutical industry. In 2002, during a short leave from Lilly, Mr. Schacht was co-founder, President and CEO of Artesian Therapeutics, a Gaithersburg, MD cardiovascular drug discovery start-up. Mr. Schacht began his career at Lilly in 1990 as a medicinal chemist, and spent 5 years in the laboratory working to discover pharmaceuticals to treat cardiovascular disorders. Schacht studied Organic chemistry at the University of Illinois, receiving his Bachelors of Science degree in 1990.

    Aaron Schacht

    CEO
    BIomEdit

    Prior to this role, Mr. Aaron Schacht was the Vice President of Global Research and Development / Regulatory Affairs at Elanco Animal Healthheld. Before that, he held the role of Global Brand Development Leader – Pain in Lilly Biomedicines. He was the global leader for product development and commercialization activities for LY2951742 – Lilly’s novel CGRP neutralizing antibody – a new potential treatment for prevention of Migraine and Cluster Headache. In 2012, Schacht joined Lilly Biomedicines as Senior Advisor – Strategy & Business Development for Lilly BioMedicines. His responsibilities included oversight of Therapeutic Strategy development, R&D Portfolio Management, and Business Development for Lilly BioMedicines – Lilly’s largest business unit. Past roles included serving as Executive Director, Global External R&D, at Eli Lilly and Company, where he was responsible for implementation of strategies which aim to leverage novel approaches to external partnerships to augment Lilly’s access to pharmaceutical innovation as well as Executive Director of LRL (Lilly Research Labs) Strategy, Portfolio Management and Project Management where he was responsible for strategic planning, R&D portfolio and project management. Prior to these roles, he was Director, Innovation Center in the eLilly organization where he focused on the exploration, incubation and implementation of new business models and capabilities relevant to the strategic evolution of the pharmaceutical industry. In 2002, during a short leave from Lilly, Mr. Schacht was co-founder, President and CEO of Artesian Therapeutics, a Gaithersburg, MD cardiovascular drug discovery start-up. Mr. Schacht began his career at Lilly in 1990 as a medicinal chemist, and spent 5 years in the laboratory working to discover pharmaceuticals to treat cardiovascular disorders. Schacht studied Organic chemistry at the University of Illinois, receiving his Bachelors of Science degree in 1990.

  • Author:

    Chuck Latham

    CEO
    H&C Animal Health

    Chuck Latham

    CEO
    H&C Animal Health
  • Author:

    Candise Goodwin

    Founder
    Outlier Advisors

    Candise Goodwin

    Founder
    Outlier Advisors
  • Author:

    Dr. Ralph Heuser

    Partner
    Stonehaven Cozmix Group

    Dr. Ralph Heuser

    Partner
    Stonehaven Cozmix Group
  • Author:

    Andrew Van Kessel

    Associate Director Research
    VIDO

    Andrew Van Kessel

    Associate Director Research
    VIDO
  • Author:

    Dr. Jürg Baggenstoss

    Partner
    Stonehaven Cozmix Group

    Dr. Jürg Baggenstoss

    Partner
    Stonehaven Cozmix Group
  • Author:

    Sabine Koelle

    Professor of Anatomy and Developmental Biology
    University College Dublin

    Sabine Koelle

    Professor of Anatomy and Developmental Biology
    University College Dublin
  • Author:

    Dawn Howard

    Chief Executive Officer
    NOAH

    Dawn Howard

    Chief Executive Officer
    NOAH
  • Author:

    Dr. David Hodges

    Founder
    Stellar Vets

    Dr. David Hodges

    Founder
    Stellar Vets
  • Author:

    Piers Hampson

    Head of Product - MAHI Companion Animal
    MSD Animal Health

    Piers Hampson

    Head of Product - MAHI Companion Animal
    MSD Animal Health
  • Author:

    Charles Cosgrave

    Managing Director
    Village Vets

    Charles Cosgrave

    Managing Director
    Village Vets
  • Author:

    Peter Michel

    Healthcare Investor
    Permira

    Peter Michel

    Healthcare Investor
    Permira
  • Author:

    Andrea Iucci

    Senior Vice President Europe
    IDEXX

    Andrea Iucci

    Senior Vice President Europe
    IDEXX
  • Author:

    Tiffany Wood

    Co-Founder and CEO
    Dyneval

    Tiffany Wood

    Co-Founder and CEO
    Dyneval
  • Author:

    Oliver Boucher

    Senior Director
    Zoetis

    Oliver Boucher has a successful track record creating and managing start-ups and executing strategic transactions at Board level on both the buy-side and sell-side of the life science business-to-business (B2B) market within the pharmaceutical and diagnostics industries. He also has significant experience in fund-raising, both dilutive and non-dilutive. He has held senior commercial and business roles in a succession of biotech companies after having gained executive level experience for seven years as a director of business development at GSK. Before joining industry, Oliver Boucher was a patent attorney in London, Montreal and Paris. He received an MA in genetics and molecular biology from Cambridge University and earned an MBA from INSEAD Business School. Mr Boucher joined Zoetis in 2017.

    Oliver Boucher

    Senior Director
    Zoetis

    Oliver Boucher has a successful track record creating and managing start-ups and executing strategic transactions at Board level on both the buy-side and sell-side of the life science business-to-business (B2B) market within the pharmaceutical and diagnostics industries. He also has significant experience in fund-raising, both dilutive and non-dilutive. He has held senior commercial and business roles in a succession of biotech companies after having gained executive level experience for seven years as a director of business development at GSK. Before joining industry, Oliver Boucher was a patent attorney in London, Montreal and Paris. He received an MA in genetics and molecular biology from Cambridge University and earned an MBA from INSEAD Business School. Mr Boucher joined Zoetis in 2017.

  • Author:

    Trine Vatle

    Director Strategy and Operations
    PHARMAQ

    Trine Vatle

    Director Strategy and Operations
    PHARMAQ
  • Author:

    Sioned Timothy

    Technical Services Manager- Livestock
    Boehringer Ingelheim

    Sioned Timothy

    Technical Services Manager- Livestock
    Boehringer Ingelheim
  • Author:

    Martin Sutherland

    Director and General Manager
    IDEXX

    Martin Sutherland

    Director and General Manager
    IDEXX
  • Author:

    Daniella Morgan-Pascualvaca

    Chief of Staff
    Mella

    Daniella Morgan-Pascualvaca

    Chief of Staff
    Mella
  • Author:

    Mel Munro

    Global Lead Regulatory Science
    knoell

    Mel Munro

    Global Lead Regulatory Science
    knoell
  • Author:

    Philip Grose

    Associate Vice President (Operations)
    MSD Animal Health

    Philip Grose

    Associate Vice President (Operations)
    MSD Animal Health
  • Author:

    Daniel Golden

    Vice President Research, Discovery & Breakthrough Innovation
    Elanco Animal Health

    Daniel Golden

    Vice President Research, Discovery & Breakthrough Innovation
    Elanco Animal Health
  • Author:

    Steve Maughan

    President
    Stonehaven Cozmix Group

    Steve Maughan

    President
    Stonehaven Cozmix Group
  • Author:

    Paul Casady

    Senior Consultant
    Brakke Consulting

    Paul Casady

    Senior Consultant
    Brakke Consulting
  • Author:

    Martin Borchert

    R&D Director Animal Health & Nutrition
    Novozymes

    Martin Borchert

    R&D Director Animal Health & Nutrition
    Novozymes
  • Author:

    Almut Hoffman

    Head of Global Marketing Farm Animal
    Elanco

    Almut Hoffman

    Head of Global Marketing Farm Animal
    Elanco
  • Author:

    Jonathan Hunt

    MD & CEO
    Syngene

    Jonathan Hunt

    MD & CEO
    Syngene
  • Author:

    Harry Bowcott

    Senior Partner
    McKinsey & Company

    Harry Bowcott

    Senior Partner
    McKinsey & Company
  • Author:

    Qi Li

    Director
    Temasek

    Qi Li

    Director
    Temasek
  • Author:

    Natacha Jamar

    Managing Director Private Equity
    Blackstone

    Natacha Jamar

    Managing Director Private Equity
    Blackstone
  • Author:

    James Wright

    UK Country Manager
    Breedr

    James Wright

    UK Country Manager
    Breedr
  • Author:

    Robert Jones

    President
    Brakke Consulting

    Robert Jones

    President
    Brakke Consulting
  • Author:

    Carel du Marchie Sarvaas

    Executive Director
    HealthforAnimals Global Animal Health Association

    Carel du Marchie Sarvaas has been working as a senior government affairs and communications advisor in Brussels and Washington DC for 20 years.

    He will move to IFAH from EuropaBio, the Association of Biotechnology Industries, where he has been Director for Agricultural Biotechnology for some 4 years. Prior to EuropaBio, Carel worked at international consultancies and think tanks in Brussels and Washington DC, most often serving clients with science-based policy and communications challenges.

    Carel is experienced in the interplay between regulatory, political and communications issues as they relate to science, innovation and policy. A Dutch national, he is married and has four children. He has lived in South Africa, Canada, Brussels, and Paris and holds degrees from the University of Leiden and Johns Hopkins University

    Carel du Marchie Sarvaas

    Executive Director
    HealthforAnimals Global Animal Health Association

    Carel du Marchie Sarvaas has been working as a senior government affairs and communications advisor in Brussels and Washington DC for 20 years.

    He will move to IFAH from EuropaBio, the Association of Biotechnology Industries, where he has been Director for Agricultural Biotechnology for some 4 years. Prior to EuropaBio, Carel worked at international consultancies and think tanks in Brussels and Washington DC, most often serving clients with science-based policy and communications challenges.

    Carel is experienced in the interplay between regulatory, political and communications issues as they relate to science, innovation and policy. A Dutch national, he is married and has four children. He has lived in South Africa, Canada, Brussels, and Paris and holds degrees from the University of Leiden and Johns Hopkins University